Čas po diagnozi

Čas po diagnozi

Diagnoza shizofrenije lahko v vas zbudi nelagodne in nasprotujoče si občutke.

Postavitev diagnoze shizofrenije je za vsakogar neprijeten trenutek v življenju. Veliko bolnikov je prestrašenih in zaskrbljenih, nekateri pa si kljub vsemu oddahnejo, saj dobijo odgovor na številna vprašanja in občutek, da so razumljeni. Vsi ti občutki se lahko pojavijo sočasno.

Popolnoma sprejemljivo je, da ste zbegani in zaskrbljeni glede odziva okolice. Zato je pomembno, da svoje občutke zaupate zdravniku in se pogovorite o možnostih zdravljenja, ki so danes številne in učinkovito pripomorejo k okrevanju.

  1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004.
  2. Falkai P et al. World J Biol Psychiatry 2005; 6: 132–191.
  3. Kendler KS et al. Arch Gen Psychiatry 1996; 53: 1022–1031.
  4. World Health Organization. The World Health Report: 2001: Mental health: new understanding, new hope.
  5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.
  6. Lieberman JA et al. J Clin Psychiatry 1996; 57 (suppl 9): 5–9.
  7. Breier A et al. Am J Psychiatry 1994; 151: 20–26.
  8. Robinson DG et al. Am J Psychiatry 1999; 156: 544–549.
  9. National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.
  10. Howard R et al. Am J Psychiatry 2000; 157: 172–178.
  11. Angermeyer MC et al. Schizophr Bull 1990; 16: 293–307.
  12. Murray RM and Fearon P. J Psychiatr Res 1999; 33: 497–499.
  13. Lang UE et al. Cell Physiol Biochem 2007; 20: 687–702.
  14. Harrigan SM et al. Psychol Med 2003; 33: 97–110.
  15. Bottlender R et al. Schizophr Res 2003; 62: 37–44.
  16. Emsley R et al. Curr Opin Psychiatry 2008; 21: 173–177.
  17. Awad AG et al. Pharmacoeconomics 2008; 26: 149–162.
  18. Keith SJ et al. Psychiatr Serv 2004; 55: 997–1005.
  19. Lieberman JA et al. Pharmacol Rev 2008; 60: 358–403.
  20. Tandon R et al. Psychoneuroendocrinology 2003; 28 (suppl 1): 9–26.
  21. Wyatt RJ. Schizophr Bull 1991; 17: 325–351.
  22. Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241–247.
  23. Weiden PJ et al. Psychiatr Serv 2004; 55: 886–891.
  24. Koen L et al. Psychosomatics 2007; 48: 128–134.
  25. Novick D et al. Psychiatry Res 2010; 176: 109–113.
  26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27; 1603–1611.

EM-25345/201222

Sorodne vsebine

Logo Janssen | Pharmaceutical Companies of Johnson & Johnson